---
provider: claude_code
model: claude-haiku-5-5, claude-opus-5-5
cached: false
start_time: '2026-11-03T19:18:34.555945'
end_time: '2026-11-03T19:25:38.375344'
duration_seconds: 423.82
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: Arterial Tortuosity-Bone Fragility Syndrome
  mondo_id: MONDO:0971179
  category: Mendelian
  causal_genes: EMILIN1
  omim_id: OMIM:620908
  synonyms: EMILIN1-related arterial tortuosity syndrome
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-haiku-5-5
  - claude-opus-5-5
  web_search_requests: 4
  num_turns: 20
  total_cost_usd: 2.557811105
  session_id: 9acbcb80-4fa6-4b3e-8029-b608cf3109d6
  stop_reason: end_turn
  permission_denials: 4
  denied_tools:
  - Bash
  assistant_text_blocks: 4
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderAuthError
  status_code: 403
  remedy: the API key is missing, invalid, or lacks access to this endpoint
  retryable: false
- provider: claude_code
  succeeded: true
citation_count: 14
reference_validation:
  total_references: 11
  verified: 10
  not_found: 1
  unverifiable: 0
  confabulation_rate: 0.091
  relevance_assessed: 10
  on_topic: 5
  off_topic: 2
  off_topic_references:
  - PMID:40909027
  - PMC:PMC12407571
  unresolved_references:
  - PMID:16530041
  needs_review: true
  validator_version: 0.5.1
term_validation:
  total_terms: 63
  verified: 63
  not_found: 0
  obsolete: 0
  unverifiable: 0
  confabulation_rate: 0.0
  labels_checked: 9
  labels_matching: 8
  labels_variant: 1
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Arterial Tortuosity-Bone Fragility Syndrome
- **MONDO ID:** MONDO:0971179 (if available)
- **Causal gene(s):** EMILIN1
- **OMIM:** OMIM:620908
- **Synonyms:** EMILIN1-related arterial tortuosity syndrome
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **Arterial Tortuosity-Bone Fragility Syndrome** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

The Europe PMC fullTextXML endpoint returned HTTP 500. The coordinator named pmc.ncbi.nlm.nih.gov as the alternative, so I'll try that one.

## (a) Core queries for PMIDs 26462740 and 40909027

**PMID 26462740**
- Title: Diagnostic Exome Sequencing Identifies a Novel Gene, EMILIN1, Associated with Autosomal-Dominant Hereditary Connective Tissue Disease.
- Journal: Human mutation, 37(1):84-97
- Year: 2016
- abstractText (verbatim, tags stripped):
> Heritable connective tissue diseases are a highly heterogeneous family of over 200 disorders that affect the extracellular matrix. While the genetic basis of several disorders is established, the etiology has not been discovered for a large portion of patients, likely due to rare yet undiscovered disease genes. By performing trio-exome sequencing of a 55-year-old male proband presenting with multiple symptoms indicative of a connective disorder, we identified a heterozygous missense alteration in exon 1 of the Elastin Microfibril Interfacer 1 (EMILIN1) gene, c.64G>A (p.A22T). The proband presented with ascending and descending aortic aneurysms, bilateral lower leg and foot sensorimotor peripheral neuropathy, arthropathy, and increased skin elasticity. Sanger sequencing confirmed that the EMILIN1 alteration, which maps around the signal peptide cleavage site, segregated with disease in the affected proband, mother, and son. The impaired secretion of EMILIN-1 in cells transfected with the mutant p.A22T coincided with abnormal protein accumulation within the endoplasmic reticulum. In skin biopsy of the proband, we detected less EMILIN-1 with disorganized and abnormal coarse fibrils, aggregated deposits underneath the epidermis basal lamina, and dermal cells apoptosis. These findings collectively suggest that EMILIN1 may represent a new disease gene associated with an autosomal-dominant connective tissue disorder.

This is the Capuano et al. 2016 paper from the earlier request. Its PMID is confirmed by the core query.

**PMID 40909027**
- Title: Elastin Microfibril Interface-Located Protein 1 (EMILIN1) Mutation Mimicking Axonal Hereditary Motor Sensory Neuropathy.
- Journal: Cureus, 17(8):e89357
- Year: 2025
- abstractText (verbatim, tags stripped):
> Hereditary peripheral neuropathies may present as isolated neuropathy or as a part of a more complex neurological disorder. Hereditary motor sensory neuropathy is the most common form of hereditary neuropathy. The discovery of an increasing number of causative genes over the years has significantly complicated the classification of hereditary motor sensory neuropathy. Mutations in elastin microfibril interface-located protein 1 (EMILIN1) are linked to a range of connective tissue disorders, involving the vascular system, skeletal structures, and possibly the nervous system. We report a case of axonal hereditary motor sensory neuropathy associated with a mutation in the EMILIN1 gene.

## (b) Full text of PMID 36351433 (Adamo et al., AJHG 2022)

**Access problems.** The Europe PMC core query returned PMCID PMC9748297. The fullTextXML endpoint (https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9748297/fullTextXML) returned HTTP 500, which is a permanent failure, so I did not retry it. I then read the PMC page you suggested (https://pmc.ncbi.nlm.nih.gov/articles/PMC9748297/).

**Coverage.** The PMC page was truncated at character 39,409 of 170,408. The verbatim text runs through the start of Table 1 and stops there. The tool then returned a model-generated summary of the rest, and its last ~31,000 characters were not read at all. Everything below marked "summary" comes from that summary, not from verbatim text, and should be checked against the article before use. Items the verbatim text does not reach are reported as "not verified."

**Verbatim text read (sections named):**

- *Summary:* "Here, we report bi-allelic _EMILIN1_ loss-of-function variants causative for an entity combining cutis laxa, arterial tortuosity, aneurysm formation, and bone fragility, resembling autosomal-recessive cutis laxa type 1B, due to _EFEMP2_ (_FBLN4_) deficiency." Also: "In both humans and mice, absence of EMILIN1 impairs EFEMP2 extracellular matrix deposition and LOX activity resulting in impaired elastogenesis, reduced collagen crosslinking, and aberrant growth factor signaling."
- *Introduction:* "Here, we report homozygous _EMILIN1_ loss-of-function variants that impair both elastin and collagen fiber formation and cause a syndrome characterized by arterial tortuosity, aortic aneurysm formation, and bone fragility..."
- *Figure 1 legend (A):* "Craniofacial features are mild and include downslanted palpebral fissures, epicanthal folds, a convex and/or broad nasal ridge and tip, long and flat philtrum, thin upper lip, and micrognathia."
- *Figure 1 legend (B):* "...severe tortuosity of the aorta, intracranial, pulmonary, and carotid arteries in F2:IV-2..." and "Giant and progressive aortic aneurysm in F4:II-3 upon CT imaging."
- *Figure 1 legend (C):* "Conventional radiography and CT imaging showing fractures in most affected individuals."
- *Figure 1 legend (D):* "Pedigree analysis of affected individuals in four unrelated families carrying _EMILIN1_ variants confirms segregation of the variants with the phenotype."
- *Subjects and methods, Clinical assessment:* skin biopsies for fibroblast culture were taken from "F1:IV-1, F1:IV-2, F3:III-1, F4:II-3". Aortic tissue came from "F2:IV-2".
- *Subjects and methods, Exome sequencing:* "Allele frequencies were evaluated using the gnomAD population database."
- *Antibodies:* anti-Phospho-Smad2 (#ab3849, IHC 1:200) and anti-CTGF (#ab6992, IHC 1:200) were used.
- *Introduction, on mice:* "Genetic ablation of _Emilin1_ in mice causes elastic fiber defects in aorta and skin..."

**Summary-derived content (unverified verbatim):**

1. **Patients and variants.** Six affected males from four unrelated families. Recorded ages are at last evaluation.
   - Family 1 (F1:IV-1 proband, age 7 y; F1:IV-2, age 5 y): homozygous c.831dup, p.Ala278Serfs*11. Consanguineous. Middle-Eastern.
   - Family 2 (F2:IV-2, age 3 mo; F2:IV-3, age 2 wk): homozygous c.151del, p.Arg51Glyfs*14. Consanguineous. Middle-Eastern. F2:IV-2 has 47,XXY.
   - Family 3 (F3:III-1, age 6 mo): compound heterozygous c.119dup (p.Ser40Argfs*34, maternal) and c.2457_2482dup (p.Gln828Leufs*59, paternal). Not consanguineous. European white. This conflicts with the verbatim "homozygous" in the Introduction.
   - Family 4 (F4:II-3, age 18 mo): homozygous c.1606C>T, p.Gln536*. Not consanguineous. Hispanic American.
   - Country of origin and report date are not given beyond the 2022 publication date.

2. **Clinical features (counts from Table 1, per the summary):**
   - Arterial: aortic tortuosity 6/6; tortuosity of other arteries 5/5 assessed; aortic root dilatation 4/6; coarctation 2/6; arterial stenosis 2/6; dissection 0/6.
   - Aneurysm: aortic root aneurysm in four subjects (F2:IV-3 at birth, F3:III-1 at about 1 year, F4:II-3 at about 1 year, F1:IV-1 at 7 years).
   - Fractures: 5/6. Parietal fractures in F2:IV-3 and F3:III-1.
   - Osteopenia/BMD: osteopenia on densitometry at 6 weeks in F2:IV-2. Normal in the family 1 siblings.
   - Skin/cutis laxa: cutis laxa 3/6; thin velvety skin 3/5.
   - Hernia: right inguinal hernia in F1:IV-1, surgically repaired.
   - Joint laxity: 3/6. Arachnodactyly in F1:IV-1.
   - Facial: as in the verbatim Figure 1A legend, plus blue sclerae 3/5.
   - Cardiac: aortic regurgitation in F1:IV-2 and F4:II-3. Ostium secundum ASD in F4:II-3. Severe LV hypertrophy with refractory hypertension in F2:IV-2.
   - Pulmonary: neonatal respiratory distress 3/6.
   - Renal: hydronephrosis 4/6.
   - Neurologic: seizures 2/6. Corpus callosum hypoplasia in one family 2 sibling on MRI.
   - Deaths: F2:IV-2 died of postoperative complications at about 3 months.
   - Surgeries: F2:IV-2 had two repairs of stenotic aortic regions. F4:II-3 had valve-sparing aortic root, ascending, and hemiarch replacement at 18 months. F1:IV-1 had hernia repair.
   - Treatments: bisphosphonates and losartan are not mentioned.
   - Discrepancy: the text says coarctation was found in F3:III-1, but the table lists it as absent for that subject.

3. **Fibroblast findings:**
   - EFEMP2 deposition strongly reduced in F1:IV-1 and F1:IV-2.
   - LOX: total and processed LOX reduced. Activity reduced 35-70% in the EMILIN1 lines.
   - TGF-beta: total secreted TGF-beta normal. PAI1 and CTGF transcripts increased in F1:IV-2. In aortic tissue, pSMAD2 was not clearly increased, but CTGF staining was.
   - Collagen: total collagen deposition about 50% lower in long-term F1:IV-2 culture. Fibers thin and curly.
   - Crosslinking: measured only in mice.
   - BMP or other growth factors: not reported.

4. **Mouse Emilin1-/- findings:**
   - Micro-CT: decreased trabecular bone in juvenile and adult femora. Cortical bone area increased.
   - Biomechanics: stiffness increased only in adult femora. No fractures reported in mice.
   - Aorta: increased collagen I and abnormal distribution in the wall. The authors note previous reports showed no tortuosity or aneurysms in these mice.
   - Skin: strongly reduced EFEMP2 fiber formation in dermal fibroblasts. Fibril diameter larger (79 ± 10.8 nm wild-type versus 121.1 ± 28.3 nm knockout). Collagen crosslinks significantly reduced at P60.

5. **gnomAD and family count.**
   - Four unrelated families (verbatim, Figure 1D legend).
   - Methods verbatim: allele frequencies were evaluated using gnomAD.
   - Summary says all variants are absent from population databases. I did not verify this against the article's text.

**Not verified:** the Table 1 content beyond the first chunk, all of the Results text after character 39,409, the mouse and fibroblast data, and the summary's family-level details. Confirm these against the article or a further verbatim read before using them. I can continue reading the PMC page from a later offset if you want that verified.

I have enough material and am writing the report now. First I'm checking the suggested HPO, GO, CL and UBERON identifiers against the repo's term caches so none of them comes from memory.

# Arterial Tortuosity–Bone Fragility Syndrome (ATBFS; EMILIN1-related): research report

**Causal gene:** *EMILIN1* (hgnc:19880; OMIM gene *130660), elastin microfibril interfacer 1. The disease is caused by **biallelic loss-of-function variants**, inherited autosomal recessively. A separate autosomal dominant EMILIN1 phenotype exists and must not be merged with this one; see §4.

**How the sources were checked**

- **Abstracts quoted verbatim:** PMID:36351433, 16530041, 18411305, 40062121, 26462740 and 40909027. They were read from Europe PMC REST records in this session.
- **ClinGen assertion:** quoted from the repo's committed `cache/clingen/gene_validity.csv` (export of 2026-01-24).
- **Not in `references_cache/`:** none of these PMIDs is cached locally. `just fetch-reference` needed approval and was not run.
- **OMIM:** returned 403, so no clinical synopsis was read.
- **Adamo 2022 full text (PMC9748297):** only the first ~39 k of 170 k characters were read verbatim. The per-patient counts below are marked **[unverified extraction]**. They come from a fetch-tool summary of the remainder and must be checked against Table 1 before they go into YAML.
- **HPO/GO/CL/UBERON CURIEs:** read from the repo's `cache/*/terms.csv` in this session. MONDO:0971179 comes from the stub file. No CURIE was written from memory.

---

## 1. Disease information

**Overview.** ATBFS is a congenital or neonatal-onset heritable connective tissue disorder. It is closest to the autosomal recessive cutis laxa type 1 group, especially ARCL1B (EFEMP2/FBLN4). Its core features are generalized arterial tortuosity, aortic root aneurysm, and bone fragility with fractures at birth or in infancy. Cutis laxa and joint laxity occur in some patients.

**Defining source (primary literature, human + mouse + in vitro):** Adamo CS et al., *Am J Hum Genet* 2022;109(12):2230-2252, **PMID:36351433**, doi:10.1016/j.ajhg.2022.10.010.

> "Here, we report bi-allelic EMILIN1 loss-of-function variants causative for an entity combining cutis laxa, arterial tortuosity, aneurysm formation, and bone fragility, resembling autosomal-recessive cutis laxa type 1B, due to EFEMP2 (FBLN4) deficiency."

**Identifiers**

| System | ID | Source / status |
|---|---|---|
| MONDO | MONDO:0971179 "arterial tortuosity-bone fragility syndrome" | stub file (MONDO enrichment); not in `cache/mondo/terms.csv` |
| OMIM | #620908 ATBFS | given in the task; OMIM page title seen in a search result. Not read directly (403) |
| ClinGen GDV | CGGV:assertion_be7af692-0751-4da3-a24a-b28cf4675b4d-2025-06-05T160000.000Z; EMILIN1, AR, **Definitive**, SOP11, Hereditary Cardiovascular Disease GCEP, 2025-06-05 | structured database (`cache/clingen/gene_validity.csv`) |
| GenCC | submission SGC-107086.2 seen in a search result | not read |
| KEGG DISEASE | H02830, seen in a search result | not read |
| Orphanet, ICD-10, ICD-11, MeSH | **none found** | gap |

**MONDO parents** (stub): MONDO:0002254 syndromic disease, MONDO:0005385 vascular disorder, MONDO:0005516 osteochondrodysplasia, MONDO:0023603 hereditary disorder of connective tissue, MONDO:0100237 inherited cutis laxa.

**Synonyms:** ATBFS; EMILIN1-related arterial tortuosity syndrome. The 2022 paper's title phrase, "arterial tortuosity with osteopenia", is a description, not a name.

**Source type.** Everything here comes from case reports and small series: 6 patients in 4 families (Adamo 2022) plus one case (Furuta 2025). There are no registry or EHR data.

---

## 2. Etiology

- **Cause:** homozygous or compound heterozygous truncating *EMILIN1* variants that remove EMILIN-1 protein (PMID:36351433).
- **Risk factors:** consanguinity. Families 1 and 2 were consanguineous **[unverified extraction]**. Two of four families were non-consanguineous, including one compound heterozygote.
- **Environmental risk factors, protective factors, G×E:** none reported.
- **Modifiers:** none identified. One proband (F2:IV-2) also had 47,XXY **[unverified extraction]**; any modifying effect is unstudied.

---

## 3. Phenotypes

The counts are out of 6 patients from Adamo 2022 Table 1 **[unverified extraction]**. A seventh patient (Furuta 2025, PMID:40062121) is noted where present.

| Phenotype | HPO (cache-checked) | Frequency | Onset / notes |
|---|---|---|---|
| Generalized arterial tortuosity (aorta, intracranial, pulmonary, carotid) | HP:0005116 Arterial tortuosity | 6/6; also the Furuta case | Congenital. Fig. 1B legend (verbatim): "severe tortuosity of the aorta, intracranial, pulmonary, and carotid arteries in F2:IV-2" |
| Aortic root aneurysm or dilatation | HP:0002616 Aortic root aneurysm | dilatation 4/6 | Birth to 7 y; progressive. Fig. 1B (verbatim): "Giant and progressive aortic aneurysm in F4:II-3" |
| Fractures at birth or in early infancy | HP:0005855 Multiple prenatal fractures (perinatal); HP:0002757 Recurrent fractures | 5/6; also Furuta (clavicle, scapula, ribs) | Fig. 1C (verbatim): "fractures in most affected individuals". Parietal fractures in 2 patients |
| Osteopenia | HP:0000938 | 1 documented on densitometry (6 wk); normal in family 1 siblings | Bone density is inconsistent; fragility is the more reliable finding |
| Cutis laxa | HP:0000973 | 3/6; **absent** in the Furuta case | Variable |
| Thin, velvety skin | HP:0000963 Thin skin / HP:0000977 Soft skin | 3/5 | |
| Joint laxity | HP:0001382 Joint hypermobility | 3/6 | |
| Inguinal hernia | HP:0000023 | 1/6 (repaired) | |
| Blue sclerae | HP:0000592 | 3/5 | Overlaps with osteogenesis imperfecta (OI) |
| Mild craniofacial features | HP:0000494 Downslanted palpebral fissures, HP:0000286 Epicanthus, HP:0000343 Long philtrum, HP:0000219 Thin upper lip vermilion, HP:0000347 Micrognathia | not counted | Fig. 1A legend (verbatim): "Craniofacial features are mild and include downslanted palpebral fissures, epicanthal folds, a convex and/or broad nasal ridge and tip, long and flat philtrum, thin upper lip, and micrognathia." |
| Coarctation or arterial stenosis | HP:0001680, HP:0004950 | 2/6 each; text and table disagree for F3:III-1 | Furuta case: supravalvular pulmonary stenosis |
| Aortic regurgitation | HP:0001659 | 2/6 | |
| Atrial septal defect | HP:0001631 | 1/6 | |
| LV hypertrophy with refractory hypertension | HP:0001712, HP:0000822 | 1/6 | Hypertension fits the Emilin1-/- mouse (§6) |
| Neonatal respiratory distress | HP:0002098 | 3/6 | Also the Furuta case (aspiration) |
| Hydronephrosis | HP:0000126 | 4/6; also Furuta (mild, duplex system) | Possibly a urinary-tract elastic-fibre phenotype; this is inference |
| Seizures; corpus callosum hypoplasia | HP:0001250; HP:0002079 | 2/6; 1/6 | Mechanism unknown |
| Short stature, plagiocephaly, inverted nipples | HP:0004322, HP:0001357, HP:0003186 | Furuta case only | Single report |
| Arachnodactyly | HP:0001166 | 1/6 | |

**Inheritance:** HP:0000007 Autosomal recessive inheritance.

**Quality of life:** no QoL instruments have been reported. The burden is inferred from the reported complications: early aortic surgery, fractures, one postoperative death.

---

## 4. Genetic and molecular information

**Variants.** The cDNA/protein changes below are **[unverified extraction]**. The two Furuta variants are verbatim from their abstract.

| Family | Genotype | Variant(s) | Ancestry | Consanguinity |
|---|---|---|---|---|
| F1 (2 affected brothers, 7 y and 5 y) | homozygous | c.831dup, p.Ala278Serfs*11 | Middle Eastern | yes |
| F2 (2 affected brothers) | homozygous | c.151del, p.Arg51Glyfs*14 | Middle Eastern | yes |
| F3 (1) | compound heterozygous | c.119dup p.Ser40Argfs*34 / c.2457_2482dup p.Gln828Leufs*59 | European | no |
| F4 (1) | homozygous | c.1606C>T, p.Gln536* | Hispanic American | no |
| Furuta 2025 (1, 9-month-old boy) | compound heterozygous | "c.275_277delinsTT, p.(C92Ffs22) maternal variant and a c.1759G>T, p.(G587) paternal" | not stated | not stated |

- **Variant class:** all are truncating (frameshift or nonsense); the mechanism is loss of function. Every reported case is male. With n = 7 that is probably chance, since inheritance is autosomal recessive (this is an inference).
- **Population frequency:** Adamo's methods say gnomAD was checked ("Allele frequencies were evaluated using the gnomAD population database."). The claim that all variants are absent from gnomAD is **[unverified extraction]**.
- **ClinVar:** not queried; this is a gap.
- **Classification pitfall (PMID:40062121):**
  > "The lab report classified his biallelic EMILIN1 terminator variants as variants of unknown significance (VUSs) and did not postulate a possible relationship with a known autosomal recessive disorder."

**Separate dominant EMILIN1 phenotypes (keep apart from ATBFS)**

- **Capuano 2016, PMID:26462740.** A heterozygous missense variant, c.64G>A p.A22T, at the signal-peptide cleavage site segregated with disease in 3 generations. Features:
  > "ascending and descending aortic aneurysms, bilateral lower leg and foot sensorimotor peripheral neuropathy, arthropathy, and increased skin elasticity"

  The mutant protein was retained in the ER, which suggests a dominant-negative or toxic mechanism rather than null.
- **HMND10 (MONDO:0859300; OMIM 620080):** p.R250C in one family (PMID:31978608). It is already curated in the KB as the `dHMN-EMILIN1` subtype in `Distal_Hereditary_Motor_Neuronopathy_Autosomal_Dominant.yaml`. That entry correctly notes that the ClinGen Definitive assertion applies to ATBFS (AR), not to HMND10.
- **PMID:40909027 (2025):** one HMSN case report. Its abstract gives no variant details.

**Lump/split call.** I recommend **SPLIT**: ATBFS should be a DISEASE entry of its own.

- The allelic dominant disorders differ in inheritance, variant class and phenotype.
- Heterozygous parents of ATBFS patients are described as healthy (Furuta: "parents and sister healthy"). This argues against haploinsufficiency explaining the dominant phenotype.

**Epigenetic and chromosomal abnormalities:** none reported.

---

## 5. Environmental information

No environmental, lifestyle or infectious factors have been reported. The section does not apply.

---

## 6. Mechanism and pathophysiology

**Causal chain**

1. Biallelic truncating *EMILIN1* variants **lead to** absence of EMILIN-1 protein at the elastin–microfibril interface. Absence is inferred from the variant class plus fibroblast and mouse data.
2. Loss of EMILIN-1 **results in** impaired extracellular deposition of EFEMP2 (fibulin-4) and reduced LOX activity. This was demonstrated in patient fibroblasts and Emilin1-/- mice (PMID:36351433):
   > "In both humans and mice, absence of EMILIN1 impairs EFEMP2 extracellular matrix deposition and LOX activity resulting in impaired elastogenesis, reduced collagen crosslinking, and aberrant growth factor signaling."

   Reported magnitude: LOX activity fell 35–70% in fibroblasts **[unverified extraction]**.
3. The pathway then branches:
   - **3a. Elastic fibres.** Reduced EFEMP2–LOX function **leads to** impaired elastic fibre assembly in the aorta and skin. Downstream this gives **arterial tortuosity, aortic root aneurysm and cutis laxa**. These are the same downstream features as ARCL1B; mechanistic convergence on the EFEMP2–LOX axis is the authors' interpretation.
   - **3b. Collagen.** Reduced LOX-mediated crosslinking **results in** abnormal collagen fibrils. In mouse skin, fibril diameter rose from about 79 to about 121 nm, crosslinks were reduced at P60, and fibroblasts deposited about 50% less collagen **[unverified extraction]**. Downstream this gives **bone fragility and fractures**. The link from collagen defect to fracture is inferred: the mice showed abnormal trabecular bone but no fractures (PMID:36351433):
     > "murine Emilin1-/- femora show abnormal trabecular bone formation and strength"
   - **3c. Growth-factor signalling.** Loss of EMILIN-1 **removes** its inhibition of proTGF-β maturation. This was shown in mice (PMID:16530041):
     > "Emilin1 inhibits TGF-beta signaling by binding specifically to the proTGF-beta precursor and preventing its maturation by furin convertases in the extracellular space."

     The result is increased TGF-β signalling in the vessel wall. Downstream this plausibly contributes to **hypertension and smaller vessel calibre**, and in the mice the hypertension was rescued by removing one *Tgfb1* allele. In patients the TGF-β readout was mixed: CTGF and PAI1 were up, pSMAD2 was not clearly increased, and total secreted TGF-β was normal **[unverified extraction]**. Calling TGF-β the driver of the human vascular phenotype is therefore **not established**.
   - **3d. Lymphatics (mouse only).** In mice, Emilin1 deficiency **causes** lymphatic hyperplasia, fewer anchoring filaments and mild lymphoedema (PMID:18411305). No human lymphatic phenotype has been reported, so this is a model-only branch.

**Suggested terms (cache-checked)**

- **GO processes:** GO:0048251 elastic fiber assembly (DECREASED); GO:0030199 collagen fibril organization; GO:0018057 peptidyl-lysine oxidation; GO:0004720 protein-lysine 6-oxidase activity (LOX; DECREASED); GO:0007179 TGF-β receptor signaling pathway (INCREASED, mouse); GO:0030198 extracellular matrix organization; GO:0001503 ossification; GO:0030282 bone mineralization; GO:0001946 lymphangiogenesis (mouse).
- **GO cellular components:** GO:0071953 elastic fiber; GO:0031012 extracellular matrix.
- **CL:** CL:0002620 skin fibroblast (the patient cell system); CL:0000359 vascular associated smooth muscle cell; CL:0000062 osteoblast. The osteoblast role is inferred, not tested.

**Molecular profiling, single-cell and CRISPR screens:** none reported.

---

## 7. Anatomical structures affected

- **Primary:** arterial tree, including UBERON:0000947 aorta and UBERON:0001637 artery (intracranial, carotid, pulmonary). Skeleton, including UBERON:0002483 trabecular bone tissue and UBERON:0000981 femur in mice. Skin: UBERON:0002097 skin of body, UBERON:0002067 dermis.
- **Secondary:** heart (aortic regurgitation, LVH), kidney and urinary tract (hydronephrosis), lungs (neonatal respiratory distress), CNS (seizures, corpus callosum).
- **Subcellular:** extracellular, at the elastin–microfibril interface (GO:0071953, GO:0031012).
- **Lateralization:** not applicable; the condition is systemic.

---

## 8. Temporal development

- **Onset:** congenital or neonatal. Fractures were present at birth and arterial tortuosity was seen on neonatal imaging.
- **Progression:** aortic root aneurysm is progressive, appearing between birth and 7 years. One patient needed valve-sparing root, ascending and hemiarch replacement at 18 months **[unverified extraction]**.
- **Critical period:** infancy, for both aortic surveillance and fracture prevention. This is an inference.
- **Natural history:** the oldest reported patient is about 7 years old. Adult course, life expectancy and remission are unknown.

---

## 9. Inheritance and population

- **Inheritance:** autosomal recessive (ClinGen AR, Definitive; OMIM). Penetrance in biallelic individuals appears complete for arterial tortuosity (6/6), but n is tiny.
- **Expressivity:** variable for cutis laxa, fractures and bone mineral density, including within sibships.
- **Epidemiology:** no prevalence or incidence data exist; 7 cases are published. A dismech prevalence record would be `CASES_IN_LITERATURE`.
- **Founder effects:** none described. Both consanguineous families were Middle Eastern, with different variants.
- **Carrier frequency, anticipation, germline mosaicism:** no data.
- **Sex ratio:** 7/7 male; probably chance (inference).

---

## 10. Diagnostics

- **Genetic testing:** exome sequencing found every case (Adamo; Furuta trio ES). *EMILIN1* should be on panels for cutis laxa, arterial tortuosity and thoracic aortic aneurysm/dissection, and on panels for OI-like fragility. Whether current commercial panels include it was not verified. CMA was normal in the Furuta case.
- **Imaging:** whole-body MRA or CT angiography for tortuosity and aneurysm, echocardiography for the aortic root, skeletal survey and DXA.
- **Skin and fibroblast studies:** these support the diagnosis but are research assays (EFEMP2 deposition, LOX activity, EM of collagen fibrils).
- **Biomarkers and omics:** none.
- **Differential diagnosis:**
  - *SLC2A10* arterial tortuosity syndrome: no fractures.
  - ARCL1B (*EFEMP2*): the closest phenocopy.
  - ARCL1A (*FBLN5*) and ARCL1C (*LTBP4*): cutis laxa with lung involvement.
  - Loeys–Dietz syndrome: tortuosity and aneurysm, but fractures are rare in infancy.
  - Osteogenesis imperfecta: fractures and blue sclerae, but no arterial tortuosity. The Furuta case was first evaluated as suspected OI.
  - Menkes disease: tortuosity plus fractures. The Furuta case had copper measured and normal.
  - Non-accidental injury: multiple infant fractures (inference).
- **Diagnostic criteria:** none established.
- **Screening:** none; cascade carrier testing is possible.

---

## 11. Outcome and prognosis

- **Mortality:** 1 of 6 died, of postoperative complications at about 3 months after two repairs of stenotic aortic segments **[unverified extraction]**.
- **Morbidity:** early aortic surgery, recurrent fractures, LVH with refractory hypertension (1 patient).
- **Survival, life expectancy, QoL, prognostic factors:** no data.

---

## 12. Treatment

No disease-specific treatment has been reported or trialled. ClinicalTrials.gov was not searched specifically, but none would be expected.

| Approach | Basis | NCIT (cache-checked) |
|---|---|---|
| Aortic root, ascending and hemiarch replacement; repair of stenoses | Reported in Adamo 2022 **[unverified extraction]** | NCIT:C15329 Surgical Procedure |
| Inguinal hernia repair | Reported (1 patient) | NCIT:C15329 |
| Orthopedic fracture care | Reported fractures; no specific regimen | NCIT:C16186 Orthopedic Surgical Procedure |
| Antihypertensive or angiotensin-receptor blocker therapy | **No report.** The TGF-β rationale comes from the mouse (PMID:16530041); bisphosphonates and losartan are not mentioned in the paper | NCIT:C15986 Pharmacotherapy (only if a source appears) |
| Genetic counseling | AR recurrence risk of 25% | NCIT:C15240 Genetic Counseling |
| Supportive care | | NCIT:C15747 Supportive Care |

Pharmacogenomics and advanced therapeutics: none.

---

## 13. Prevention

- **Primary prevention:** carrier and cascade testing in families, and prenatal or preimplantation testing once the familial variants are known. This follows from AR inheritance; there is no published guideline.
- **Tertiary prevention:** serial aortic imaging and fracture-aware handling. This is an inference from the phenotype, not guideline-based.
- **Vaccination, public health measures, prophylaxis:** not applicable.

---

## 14. Other species

- **Naturally occurring disease:** no OMIA entry was searched; none is known.
- **Orthologs:** mouse *Emilin1*; zebrafish *emilin1a/emilin1b*. Zebrafish *emilin1a* knockdown was used for the HMND10 phenotype (PMID:31978608), not for ATBFS. NCBI Gene IDs were not looked up.

---

## 15. Model organisms

**Emilin1-/- mouse** (evidence source MODEL_ORGANISM)

- **Vascular** (PMID:16530041):
  > "Emilin1 knockout animals display increased blood pressure, increased peripheral vascular resistance, and reduced vessel size"

  Removing one *Tgfb1* allele rescued the phenotype.
- **Elastic fibres, skin and aorta:** elastic fibre defects. EFEMP2 deposition, LOX activity and collagen crosslinking were reduced and fibrils were enlarged (PMID:36351433; details **[unverified extraction]**).
- **Bone:** abnormal trabecular bone formation and strength (PMID:36351433, verbatim above). Trabecular bone was decreased while cortical area was increased; no fractures were seen **[unverified extraction]**.
- **Lymphatics** (PMID:18411305):
  > "Emilin1 deficiency … results in hyperplasia, enlargement, and frequently an irregular pattern of superficial and visceral lymphatic vessels and in a significant reduction of anchoring filaments"

- **Fidelity:**
  - It **reproduces** the molecular axis (EFEMP2–LOX–collagen crosslinking) and the trabecular bone defect.
  - It **does not reproduce** arterial tortuosity or aneurysm; the paper says earlier reports found none **[unverified extraction]**.
  - It **does not reproduce** fractures.

  For dismech this means `PARTIALLY_RECAPITULATES` for bone, and a candidate `FAILS_TO_RECAPITULATE` plus a `HUMAN_MODEL_MISMATCH` discussion for the vascular tortuosity node.

**Patient skin fibroblasts** (IN_VITRO), from F1:IV-1, F1:IV-2, F3:III-1 and F4:II-3 (verbatim methods). They show reduced EFEMP2 deposition, reduced LOX activity and reduced collagen deposition.

---

## Gaps for curation

1. Read Adamo 2022 Table 1 and the Results in full to confirm the counts, variants and mouse data marked unverified.
2. Look up Orphanet, ICD and MeSH codes; none was found.
3. Look up ClinVar records for the published variants.
4. Run `just fetch-reference` for PMID:36351433, 16530041, 18411305, 40062121, 26462740, 40909027 and 31978608 before quoting snippets.
5. Check whether a GeneReviews chapter exists with `just check-genereviews`. None was found in this search.

## Sources

- Adamo CS et al. 2022, AJHG, PMID:36351433: [Cell](https://www.cell.com/ajhg/fulltext/S0002-9297(22)00458-X), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S000292972200458X), [PMC9748297](https://pmc.ncbi.nlm.nih.gov/articles/PMC9748297/)
- Furuta Y et al. 2025, Cureus, PMID:40062121: [PMC11890521](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890521/), [Cureus](https://www.cureus.com/articles/339249-correcting-lab-misinterpretations-of-variants-of-unknown-significance-a-case-study-of-emilin1-variants-in-an-autosomal-recessive-disorder)
- Zacchigna L et al. 2006, Cell, PMID:16530041: [PubMed](https://pubmed.ncbi.nlm.nih.gov/16530041/)
- Danussi C et al. 2008, Mol Cell Biol, PMID:18411305 (Europe PMC record)
- Capuano A et al. 2016, Hum Mutat, PMID:26462740: [Ambry summary](https://www.ambrygen.com/science/peer-reviewed-publication/11/diagnostic-exome-sequencing-identifies-a-novel-gene-emilin1-associated-with-autosomal-dominant-hereditary-connective-tissue-disease)
- PMID:31978608 (HMND10 family, p.R250C): the title is cached in the repo's `references_cache/`. No abstract was read this session.
- EMILIN1 HMSN case, 2025, PMID:40909027: [PMC12407571](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407571/)
- OMIM #620908 (not readable, 403): [OMIM](https://www.omim.org/entry/620908); OMIM gene *130660: [OMIM](https://www.ncbi.nlm.nih.gov/omim/130660)
- GenCC SGC-107086.2: [GenCC](https://thegencc.org/submissions/SGC-107086.2); KEGG H02830: [KEGG](https://www.kegg.jp/entry/H02830+-ja); MalaCards: [MalaCards](https://malacards.org/card/arterial_tortuosity_bone_fragility_syndrome)
- ClinGen GDV: `cache/clingen/gene_validity.csv`, CGGV:assertion_be7af692-0751-4da3-a24a-b28cf4675b4d-2025-06-05T160000.000Z

## Reference Validation

Checked with `linkml-reference-validator` 0.5.1.

| Outcome | Count |
| --- | --- |
| References checked | 11 |
| Resolved | 10 |
| Unresolved (possible confabulation) | 1 |
| Unverifiable | 0 |
| References weighed for topical relevance | 10 |
| On topic | 5 |
| Off topic | 2 |

### Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

- `PMID:16530041` (6 mentions) - Identifier did not resolve to a record

### References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

- `PMID:40909027` (3 mentions) - Elastin Microfibril Interface-Located Protein 1 (EMILIN1) Mutation Mimicking Axonal Hereditary Motor Sensory Neuropathy.
  - shared terms: emilin1
- `PMC:PMC12407571` (3 mentions) - Elastin Microfibril Interface-Located Protein 1 (EMILIN1) Mutation Mimicking Axonal Hereditary Motor Sensory Neuropathy.
  - shared terms: emilin1

Weighed against this report's own most characteristic terms: `emilin1`, `aortic`, `unverified`, `fracture`, `arterial`, `patient`, `variant`, `tortuosity`, `aneurysm`, `extraction`, `bone`, `skin`, `adamo`, `mouse`, `phenotype`, `root`, `cutis`, `disease`, `laxa`, `fragility`.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 63 |
| Resolved | 63 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 0 |
| Terms whose name was checked | 9 |
| Terms named correctly | 8 |
| Terms named as a **different** term | 0 |
| Terms whose name is worth a second look | 1 |

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0002098` (1 mention) - the report calls it "Neonatal respiratory distress"; HP calls it **Respiratory distress**

Every term resolved, and every label the report gave matched.